Financing ·
Endovia Health Sciences closes $500K tranche of secured convertible debt financing from C/M Capital Master Fund
EDVAEndovia Health Sciences, Inc.
Endovia Health Sciences, Inc. closed an initial $500,000 tranche of secured convertible debt financing from C/M Capital Master Fund, LP on September 22, 2026. This amount represents the first portion of a previously announced aggregate $1 million investment commitment intended to support the regulatory advancement and commercialization of CannEpil®, an exclusive global license acquired from Argent BioPharma Limited. The capital will fund Endovia’s U.S. FDA-regulated veterinary development program for canine oncology pain management, in collaboration with Lupvindol Biosciences Ltd., as well as international commercialization initiatives. The company operates in the cannabinoid health sciences industry, focusing on pharmaceutical development and therapeutics.